Global Oral Anticoagulants Market By Type (Proximal Deep Vein Thrombosis (Dvt), Arterial and Venous Thrombosis, Paroxysmal Nocturnal Haemoglobinuria, and Others), By Application (Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Retail Pharmacies), By Region and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2019-2028
- Published date: Apr 2022
- Report ID: 30081
- Number of Pages: 238
- Format:
- keyboard_arrow_up
- 1. Oral Anticoagulants Market Introduction
- 1.1. Definition
- 1.2. Taxonomy
- 1.3. Research Scope
- 2. Executive Summary
- 2.1. Key Findings by Major Segments
- 2.2. Top strategies by Major Players
- 3. Global Oral Anticoagulants Market Overview
- 3.1. Oral Anticoagulants Market Dynamics
- 3.1.1. Drivers
- 3.1.2. Opportunities
- 3.1.3. Restraints
- 3.1.4. Challenges
- 3.2. PESTLE Analysis
- 3.3. Opportunity Map Analysis
- 3.4. PORTER'S Five Forces Analysis
- 3.5. Market Competition Scenario Analysis
- 3.6. Product Life Cycle Analysis
- 3.7. Opportunity Orbits
- 3.8. Manufacturer Intensity Map
- 3.1. Oral Anticoagulants Market Dynamics
- 4. Global Oral Anticoagulants Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
- 4.1. Global Oral Anticoagulants Market Analysis by Type: Introduction
- 4.2. Market Size and Forecast by Region
- 4.3. Proximal deep vein thrombosis (DVT)
- 4.4. Arterial and venous thrombosis
- 4.5. Paroxysmal nocturnal haemoglobinuria
- 4.6. Others
- 5. Global Oral Anticoagulants Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
- 5.1. Global Oral Anticoagulants Market Analysis by Application: Introduction
- 5.2. Market Size and Forecast by Region
- 5.3. Hospital Pharmacies
- 5.4. Retail Pharmacies
- 5.5. Drug Stores
- 5.6. Retail pharmacies
- 6. Global Oral Anticoagulants Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
- 6.1. North America
- 6.1.1. North America Oral Anticoagulants Market: Regional Trend Analysis
- 6.1.1.1. US
- 6.1.1.2. Canada
- 6.1.1.3. Mexico
- 6.1.1. North America Oral Anticoagulants Market: Regional Trend Analysis
- 6.2.1. Europe
- 6.2.1. Europe Oral Anticoagulants Market: Regional Trend Analysis
- 6.2.1.1. Germany
- 6.2.1.2. France
- 6.2.1.3. UK
- 6.2.1.4. Russia
- 6.2.1.5. Italy
- 6.2.1.6. Rest of Europe
- 6.2.1. Europe Oral Anticoagulants Market: Regional Trend Analysis
- 6.3. Asia-Pacific
- 6.3.1. Asia-Pacific Oral Anticoagulants Market: Regional Trend Analysis
- 6.3.1.1. China
- 6.3.1.2. Japan
- 6.3.1.3. Korea
- 6.3.1.4. India
- 6.3.1.5. Rest of Asia
- 6.3.1. Asia-Pacific Oral Anticoagulants Market: Regional Trend Analysis
- 6.4. Latin America
- 6.4.1. Latin America Oral Anticoagulants Market: Regional Trend Analysis
- 6.4.1.1. Brazil
- 6.4.1.2. Argentina
- 6.4.1.3. Rest of Latin America
- 6.4.1. Latin America Oral Anticoagulants Market: Regional Trend Analysis
- 6.5. Middle East and Africa
- 6.5.1. Middle East and Africa Oral Anticoagulants Market: Regional Trend Analysis
- 6.5.1.1. GCC
- 6.5.1.2. South Africa
- 6.5.1.3. Israel
- 6.5.1.4. Rest of MEA
- 6.5.1. Middle East and Africa Oral Anticoagulants Market: Regional Trend Analysis
- 6.1. North America
- 7. Global Oral Anticoagulants Market Competitive Landscape, Market Share Analysis, and Company Profiles
- 7.1. Market Share Analysis
- 7.2. Company Profiles
- 7.3. The Medicines Company
- 7.3.1. Company Overview
- 7.3.2. Financial Highlights
- 7.3.3. Product Portfolio
- 7.3.4. SWOT Analysis
- 7.3.5. Key Strategies and Developments
- 7.4. Urigen Pharmaceuticals
- 7.4.1. Company Overview
- 7.4.2. Financial Highlights
- 7.4.3. Product Portfolio
- 7.4.4. SWOT Analysis
- 7.4.5. Key Strategies and Developments
- 7.5. Cellceutix
- 7.5.1. Company Overview
- 7.5.2. Financial Highlights
- 7.5.3. Product Portfolio
- 7.5.4. SWOT Analysis
- 7.5.5. Key Strategies and Developments
- 7.6. Eisai
- 7.6.1. Company Overview
- 7.6.2. Financial Highlights
- 7.6.3. Product Portfolio
- 7.6.4. SWOT Analysis
- 7.6.5. Key Strategies and Developments
- 7.7. Sagent Pharmaceuticals
- 7.7.1. Company Overview
- 7.7.2. Financial Highlights
- 7.7.3. Product Portfolio
- 7.7.4. SWOT Analysis
- 7.7.5. Key Strategies and Developments
- 7.8. Daiichi Sankyo
- 7.8.1. Company Overview
- 7.8.2. Financial Highlights
- 7.8.3. Product Portfolio
- 7.8.4. SWOT Analysis
- 7.8.5. Key Strategies and Developments
- 7.9. Armetheon
- 7.9.1. Company Overview
- 7.9.2. Financial Highlights
- 7.9.3. Product Portfolio
- 7.9.4. SWOT Analysis
- 7.9.5. Key Strategies and Developments
- 7.10. AspenBoehringer Ingelheim
- 7.10.1. Company Overview
- 7.10.2. Financial Highlights
- 7.10.3. Product Portfolio
- 7.10.4. SWOT Analysis
- 7.10.5. Key Strategies and Developments
- 7.11. BMS
- 7.11.1. Company Overview
- 7.11.2. Financial Highlights
- 7.11.3. Product Portfolio
- 7.11.4. SWOT Analysis
- 7.11.5. Key Strategies and Developments
- 7.12. Johnson & Johnson
- 7.12.1. Company Overview
- 7.12.2. Financial Highlights
- 7.12.3. Product Portfolio
- 7.12.4. SWOT Analysis
- 7.12.5. Key Strategies and Developments
- 7.13. Sanofi
- 7.13.1. Company Overview
- 7.13.2. Financial Highlights
- 7.13.3. Product Portfolio
- 7.13.4. SWOT Analysis
- 7.13.5. Key Strategies and Developments
- 7.14. Pfizer Inc.
- 7.14.1. Company Overview
- 7.14.2. Financial Highlights
- 7.14.3. Product Portfolio
- 7.14.4. SWOT Analysis
- 7.14.5. Key Strategies and Developments
- 7.15. AstraZeneca
- 7.15.1. Company Overview
- 7.15.2. Financial Highlights
- 7.15.3. Product Portfolio
- 7.15.4. SWOT Analysis
- 7.15.5. Key Strategies and Developments
- 7.16. Bayer
- 7.16.1. Company Overview
- 7.16.2. Financial Highlights
- 7.16.3. Product Portfolio
- 7.16.4. SWOT Analysis
- 7.16.5. Key Strategies and Developments
- 7.17. Cellceutix
- 7.17.1. Company Overview
- 7.17.2. Financial Highlights
- 7.17.3. Product Portfolio
- 7.17.4. SWOT Analysis
- 7.17.5. Key Strategies and Developments
- 7.18. Cosmo Pharmaceuticals
- 7.18.1. Company Overview
- 7.18.2. Financial Highlights
- 7.18.3. Product Portfolio
- 7.18.4. SWOT Analysis
- 7.18.5. Key Strategies and Developments
- 7.19. CSL Behring
- 7.19.1. Company Overview
- 7.19.2. Financial Highlights
- 7.19.3. Product Portfolio
- 7.19.4. SWOT Analysis
- 7.19.5. Key Strategies and Developments
- 7.20. Eisai
- 7.20.1. Company Overview
- 7.20.2. Financial Highlights
- 7.20.3. Product Portfolio
- 7.20.4. SWOT Analysis
- 7.20.5. Key Strategies and Developments
- 7.21. GSK
- 7.21.1. Company Overview
- 7.21.2. Financial Highlights
- 7.21.3. Product Portfolio
- 7.21.4. SWOT Analysis
- 7.21.5. Key Strategies and Developments
- 7.22. Val
- 7.22.1. Company Overview
- 7.22.2. Financial Highlights
- 7.22.3. Product Portfolio
- 7.22.4. SWOT Analysis
- 7.22.5. Key Strategies and Developments
- 8. Assumptions and Acronyms
- 9. Research Methodology
- 10. Contact
- 1. Oral Anticoagulants Market Introduction
- The Medicines Company
- Urigen Pharmaceuticals
- Cellceutix
- Eisai
- Sagent Pharmaceuticals
- Daiichi Sankyo
- Armetheon
- AspenBoehringer Ingelheim
- BMS
- Johnson & Johnson
- Sanofi Company Profile
- Pfizer Inc Company Profile
- AstraZeneca Plc Company Profile
- Bayer AG Company Profile
- Cosmo Pharmaceuticals
- CSL Behring
- GSK
- Val
- settingsSettings
Our Clients
✖
Request a Sample Report
We'll get back to you as quickly as possible
Single User
$5,999
$2,999
USD / per unit
save 50% |
Multi User
$7,999
$3,499
USD / per unit
save 55% |
Corporate User
$12,999
$4,499
USD / per unit
save 65% | |
---|---|---|---|
e-Access | |||
Data Set (Excel) | |||
Company Profile Library Access | |||
Interactive Dashboard | |||
Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
Accessibility | 1 User | 2-5 User | Unlimited |
Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
Buy Now ($ 2,999) | Buy Now ($ 3,499) | Buy Now ($ 4,499) |